More than 20 drugmakers have announced US drug-pricing agreements

More than 20 pharmaceutical companies have now publicly announced US drug-pricing agreements with the Trump administration, according to a Reuters tally published September 1, 2026 ^[1]. A second wave announced in late August added nine companies, many of them smaller biotechs, that agreed to sell drugs to state Medicaid programs at "most-favoured-nation" prices — meaning prices tied to what other wealthy countries pay ^[1].

The deals follow a first wave struck with 17 large drugmakers starting in 2025, which included most-favored-nation pricing commitments, sales through the government's TrumpRx.gov platform, and US investment pledges in exchange for relief from threatened pharmaceutical tariffs ^[1]. Reuters notes that US prescription prices are often nearly three times higher than those paid in other developed countries ^[1]. The late-August wave was reported to include roughly $19.6 billion in additional US manufacturing commitments.

What the GLP-1 deals actually set

Two of the agreements directly affect people taking or considering GLP-1 medicines.

Novo Nordisk agreed in November to cut prices for its semaglutide products, including Wegovy and Ozempic, through Medicare, Medicaid and a direct-to-patient cash channel ^[1]. Under that deal, Ozempic and Wegovy drop from $1,000 and $1,350 per month, respectively, to $350 per month when purchased through TrumpRx ^[1]. Novo also agreed to offer insulins including NovoLog and Tresiba at $35 per month through the platform ^[1].

Eli Lilly agreed in November to offer Medicare beneficiaries its obesity medicines Zepbound (tirzepatide) and orforglipron — branded Foundayo — at no more than $50 per month ^[1]. For self-pay patients through LillyDirect, the Zepbound multidose pen is priced at $299 per month at the lowest dose, with higher doses priced up to $449, while Foundayo starts at $149 per month at its lowest dose ^[1]. Lilly also agreed to sell the diabetes drug Trulicity at $389 per month through TrumpRx ^[1]. Foundayo, Lilly's weight-loss pill, won US approval in April 2026 ^[1].

Other deals cover non-GLP-1 categories: Pfizer's discounts of up to 85% on certain brands through TrumpRx, AstraZeneca discounts up to 80%, Merck's diabetes drugs Januvia and Janumet at about 70% off list, Amgen's Repatha at $239 a month, and Regeneron's Praluent cut to $225 from $537 ^[1]. Some terms remain undisclosed — Johnson & Johnson's January agreement did not specify revised prices or which medicines are covered ^[1].

The newer, smaller-company deals are mostly Medicaid-focused. Astellas, Kyowa Kirin, CSL, BridgeBio, Sun Pharma, UCB and BeOne agreed to discounted Medicaid pricing in exchange for tariff relief or protection from future pricing mandates; CSL also pledged $1.5 billion in Illinois manufacturing and more than 1,100 jobs ^[1]. Whether any of these smaller agreements touch GLP-1 products is not stated in the Reuters tally.

Why it matters for patients

The headline numbers are cash prices and government-program prices, not what most commercially insured people pay at the pharmacy counter. For someone paying out of pocket, the $350 semaglutide and $299 tirzepatide figures are concrete reference points against list prices of $1,000 to $1,350 a month ^[1]. For people on Medicare, the $50-per-month caps for Zepbound and Foundayo are a separate commitment ^[1].

These cash and government prices sit alongside a broader cost picture that is still climbing. PwC's Behind the Numbers analysis projects a 9% medical cost trend in 2027, the fifth straight year of elevated healthcare inflation, and more than 85% of surveyed health plan actuaries said pharmacy costs are rising faster than overall medical costs ^[2]. PwC points to GLP-1 utilization as a central driver, with prescription volume rising year over year and broader indications — obesity, cardiovascular disease, chronic kidney disease, sleep apnea and MASH — expanding the eligible population ^[2]. New oral formulations could widen adoption further by removing injection barriers ^[2].

That tension matters: lower list-adjacent prices do not automatically mean employers and plans will broaden coverage, and some employers are scaling back GLP-1 benefits ^[2].

What happens next

TrumpRx.gov was slated to launch in early 2026, according to a senior administration official cited by Reuters ^[1]. Reuters reported in June 2026 that small and mid-size companies had been slow to sign on, a gap the late-August wave partly closed ^[1]. Whether more GLP-1-related agreements follow, and how quickly each announced price takes effect, is not specified in the sources.